Expansion into biologics Sandoz recently invested $400 million in a biologics manufacturing plant in Slovenia, showcasing a strategic move towards expanding its product portfolio and capabilities in the biologics market.

Strategic hiring for cybersecurity The appointment of Indranil Chatterjee as Director Cyber Security indicates a focus on enhancing cybersecurity measures, presenting an opportunity for cybersecurity solution providers to engage with Sandoz.

Legal challenges with generics Legal disputes around potential generic entries for Prolia and Xgeva drugs show a need for legal support and strategic guidance, presenting opportunities for law firms or consultants specializing in pharmaceutical patent litigation.

Expert financial oversight The appointment of Graeme Pitkethly as Non-Executive Director and Chair of the Audit, Risk and Compliance Committee reflects Sandoz's commitment to financial governance, creating potential opportunities for financial advisory services to collaborate with the company.

Investment in antibiotics production Sandoz's investment in a new antibiotics production facility in Austria signals a focus on antibiotic development, highlighting potential collaborations for suppliers of equipment and technology in the antibiotic manufacturing sector.